<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969278</url>
  </required_header>
  <id_info>
    <org_study_id>GroSNaPET</org_study_id>
    <nct_id>NCT02969278</nct_id>
  </id_info>
  <brief_title>Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy</brief_title>
  <acronym>GroSNaPET</acronym>
  <official_title>Study on the Prediction of Groin Lymphonodal Status Through 18FDG-PET/CT Combined With Sentinel Lymph Node Biopsy in Bulky a/o Multifocal a/o Pretreated Vulvar Cancer, N0 at Conventional Imaging (GRO-SNaPET Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to verify the accuracy of SNB combined with 18F-FDG PET/CT in cN0 invasive&#xD;
      vulvar cancer (IVC) patients currently not candidate to SNB according to standard guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vulvar carcinoma (VC) is a rare disease (4% of gynecological cancers) and the treatment is&#xD;
      not yet universally defined. No official guidelines are currently available to define imaging&#xD;
      techniques useful for staging. In the pre-operative evaluation of the pateints, imaging&#xD;
      should assess nodal status; the available exams are:&#xD;
&#xD;
        -  CT or MRI with contrast (abdominal and pelvic with caudal scans for inguinal regions)&#xD;
&#xD;
        -  Inguinal ultrasound with US-guided biopsy/fine needle aspiration for suspicious lymph&#xD;
           nodes.&#xD;
&#xD;
      The incidence of inguinal and pelvic lymph node metastasis not diagnosed at the pre-operative&#xD;
      imaging is 10-35% as assessed after lymphadenectomy at pathology report.&#xD;
&#xD;
      Until 2009, the standard surgical treatment of vulvar cancer was represented by mono or&#xD;
      bilateral systematic lymphadenectomy (at least 70% of N0 women underwent a radical surgery&#xD;
      with the risk of severe morbidity related to the surgical procedure with no survival&#xD;
      benefit).&#xD;
&#xD;
      Inguinal lymphadenectomy shows a high rate of local and systemic complications resulting in a&#xD;
      longer hospitalization or recovery, as well as possible delays in adjuvant therapies.&#xD;
&#xD;
      Moreover, severe complications can lead to a further surgery.&#xD;
&#xD;
      Possibile complications described in literature are:&#xD;
&#xD;
        -  Lymphedema (up to 70%)&#xD;
&#xD;
        -  Infection and postoperative cellulitis (50%)&#xD;
&#xD;
        -  Inguinal suture dehiscence (between 22 and 52%)&#xD;
&#xD;
        -  Linfocysts (between 7 and 28%)&#xD;
&#xD;
        -  Deep vein thrombosis (between 5 and 8%)&#xD;
&#xD;
        -  Sepsis (1 -2%)&#xD;
&#xD;
      Since 2009, with the introduction and the validation of sentinel node biopsy (SNB), for some&#xD;
      VC it is now possible to obtain a nodal staging with minimally invasive surgery and lower&#xD;
      morbidity. However, the SNB technique is indicated if the tumor fits the following selection&#xD;
      criteria:&#xD;
&#xD;
        -  Infiltrating tumors with a diameter &lt; 40 mm;&#xD;
&#xD;
        -  Monofocal tumors;&#xD;
&#xD;
        -  Tumors distant more than 1 cm from the midline&#xD;
&#xD;
        -  Tumors near the midline with bilateral lymphatic drainage and intraoperative detection&#xD;
           of at least one sentinel node for each groin.&#xD;
&#xD;
      Consequently in many tumors diagnosed as N0 at preoperative imaging, SNB technique is not&#xD;
      indicated; these tumors still require systematic lymphadenectomy.&#xD;
&#xD;
      In this subset of patients it is important to identify new methods for preoperative&#xD;
      evaluation of nodal status or to define a sub-category of patients for which the SNB could be&#xD;
      applied.&#xD;
&#xD;
      Objective of the study is to verify, in patients actually off-label for SNB, the accuracy of&#xD;
      18FDG-PET/CT in predicting nodal status, as an indipendent method or associated with the&#xD;
      standard pre-operative imaging and the mini-invasive surgical staging.&#xD;
&#xD;
      All patients are submitted to:&#xD;
&#xD;
        -  Gynecologic visit&#xD;
&#xD;
        -  Vulvar biopsy and possible pelvic examination under anesthesia with the definition of&#xD;
           clinical extent of disease&#xD;
&#xD;
        -  Evaluation of serum tumor markers: SCC and Ca125&#xD;
&#xD;
        -  Inguinal ultrasound and possible US guided FNAC or FNAB on suspicious lymph nodes&#xD;
&#xD;
        -  CT scan (abdomen and pelvis) with contrast&#xD;
&#xD;
        -  18FDG-PET/CT&#xD;
&#xD;
        -  Lymphangioscintigraphy of inguinofemoral axis&#xD;
&#xD;
      Vulvar surgery may include:&#xD;
&#xD;
        -  Wide resection of vulvar disease&#xD;
&#xD;
        -  Emivulvectomy (anterior, posterior or lateral)&#xD;
&#xD;
        -  Simple vulvectomy&#xD;
&#xD;
        -  Radical or ultra-radical vulvectomy (with possible plastic reconstruction)&#xD;
&#xD;
      During inguinal surgery all patients will undergo:&#xD;
&#xD;
      - Sentinel node biopsy mono or bilateral followed by radical bilateral inguinal&#xD;
      lymphadenectomy&#xD;
&#xD;
      Statistical analysis will help determine the accuracy and negative predictive value of&#xD;
      FDG-PET/CT and sentinel node biopsy in predicting nodal status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy and Negative Predictive Value of sentinel node biopsy in cN0 vulvar cancer patients that do not fit for the current indications</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy and Negative Predictive Value of preoperative 18F FDG-PET/CT for the selection of cN0 patients.</measure>
    <time_frame>within the first 60 days before surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vulvar Cancer</condition>
  <arm_group>
    <arm_group_label>Vulvar cancer patients cN0 unfit for sentinel node biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All invasive vulvar cancer patients with cN0 status:&#xD;
T &gt; 4 cm;&#xD;
multicentric tumors (mono or bilateral);&#xD;
primary lesion completely excised during prior diagnostic surgery&#xD;
patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0&#xD;
previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>18FDG-PET/TC</intervention_name>
    <description>Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes</description>
    <arm_group_label>Vulvar cancer patients cN0 unfit for sentinel node biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel node biopsy</intervention_name>
    <description>Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.</description>
    <arm_group_label>Vulvar cancer patients cN0 unfit for sentinel node biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  ECOG â‰¤ 2&#xD;
&#xD;
          -  Adequate respiratory, hepatic, cardiac, bone marrow and renal function (creatinine&#xD;
             clearance&gt; 60 mL/min according to the Cockroft formula)&#xD;
&#xD;
          -  Patient psychologically able to follow the study procedures&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
        In addition, both major criteria and at least one of the minor criteria must be present:&#xD;
&#xD;
        MAJOR CRITERIA&#xD;
&#xD;
          -  Vulvar carcinoma (stromal infiltration &gt; 1 mm); Histotypes different from squamous are&#xD;
             included&#xD;
&#xD;
          -  Negative lymphnodes at preoperative imaging&#xD;
&#xD;
        MINOR CRITERIA&#xD;
&#xD;
          -  Vulvar lesion greater than 4 cm&#xD;
&#xD;
          -  Multifocal or bilateral lesions&#xD;
&#xD;
          -  Previous complete excisional biopsy of the vulvar lesion, with absent residual disease&#xD;
&#xD;
          -  Previous neoadjuvant treatment (radiotherapy a/o sequential/concomitant chemotherapy)&#xD;
&#xD;
          -  Previous treatment with radiotherapy a/o chemotherapy (sequential a/o concomitant) for&#xD;
             previous vulvar cancer a/o other diseases&#xD;
&#xD;
          -  Previous vulvar or inguinal surgery&#xD;
&#xD;
          -  Infiltrating vulvar carcinoma with monolateral groin lymphnode involvement (N1) and&#xD;
             contralateral N0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to egg proteins and albumin&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Patients with impaired respiratory, hepatic, cardiac, bone marrow and renal function&#xD;
             (creatinine clearance&gt; 60 mL / min according to the Cockroft formula)&#xD;
&#xD;
          -  Patients with major depressive disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Gynecologic Oncology/Fondazione Policlinico Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Garganese, MD</last_name>
      <phone>00390630158545</phone>
      <email>ggarganese@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Simona M Fragomeni, MD</last_name>
      <phone>00390630158545</phone>
      <email>simona.fragomeni@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Scambia, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Giordano, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vittoria Rufini, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giorgia Garganese, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona M Fragomeni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Scambia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>vulvar cancer</keyword>
  <keyword>sentinel node biopsy</keyword>
  <keyword>inguino-femoral lymphadenectomy</keyword>
  <keyword>18F FDG- PET/TC</keyword>
  <keyword>guidelines</keyword>
  <keyword>preoperative imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

